HilleVax is a biopharmaceutical company focused on the development and commercialization of novel vaccines. Our initial program, HIL-214, is a virus-like particle (VLP) based vaccine candidate in development for the prevention of moderate-to-severe acute gastroenteritis caused by norovirus infection.
| Website | https://www.hillevax.com |
| Revenue | $19 million |
| Employees | 27 (6 on RocketReach) |
| Founded | 2021 |
| Phone | +1 617-213-5054 |
| Industry | Biotechnology Research |
| Keywords | Immunology, Vaccines, Infectious Disease, Vaccine Development, Public Health, Novel Vaccines, Viral Vaccines, Drug Development, Clinical Trials, Pharmaceutical Research, Biotechnology, Therapeutics, Prevention, Health, Medicine |
| Competitors | Johnson & Johnson, Roche, Merck & Co., Inc., Pfizer, Sanofi, GSK, AstraZeneca, Bristol Myers Squibb, Moderna Therapeutics, Novavax +37 more (view full list) |
Looking for a particular HilleVax employee's phone or email?
HilleVax Questions
The HilleVax annual revenue was $19 million in 2026.
Robert Hershberg is the Co-Founder, CEO and Chairman of the Board of HilleVax.
6 people are employed at HilleVax.
HilleVax is based in Boston, Massachusetts.
Top HilleVax Employees
-
35
-
Chao Huang
Senior Director at HilleVax
Boston, MA, US13 -
Elizabeth Maloney
Senior Accounting Manager at HilleVax
Boston, MA, US54 -
35
-
Martha O'Brien
Associate Director of Statistical Programming at HilleVax
Watertown, WI, US5+5+ -
Ivana Dinkova
HilleVax at HilleVax
Boston, MA, US11
Related Companies
G2Crowd Trusted
300K+
Plugin Users
